Showing results (61-70 of 70) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
The British Journal of Dermatology|February 5, 2020
Validation of Patient-Reported Outcomes Information System Sleep Disturbance and Sleep-Related Impairment in adults with atopic dermatitisD K Lei, M Yousaf, S R Janmohamed, et al.The Journal of Dermatological Treatment|November 23, 2020
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trialsK Reich, A M DeLozier, F P Nunes, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 13, 2024
Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2)J I Silverberg, M N Mustapa, F Reid, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 9, 2021
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trialA Wollenberg, T Nakahara, C Maari, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 25, 2023
Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysisM O Christensen, Y A Barakji, N Loft, et al.The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 15, 2023
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyK Reich, J I Silverberg, K A Papp, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 18, 2023
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent eventsR Bissonnette, L F Eichenfield, E Simpson, et al.The British Journal of Dermatology|January 17, 2021
Hand eczema in children referred for patch testing: North American Contact Dermatitis Group Data, 2000-2016J I Silverberg, E M Warshaw, H I Maibach, et al.The British Journal of Dermatology|January 30, 2020
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trialsE L Simpson, J-P Lacour, L Spelman, et al.Pageof 7